Lombard Odier Asset Management (Switzerland)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-317,901	Closed	-$2.65M	–	170
2023 Q1	$2.65M	Buy	317,901 +182,839	+135%	+$1.52M	0.23%	106
2022 Q4	$1.55M	Buy	+135,062	New	+$1.55M	0.12%	140